人类免疫缺陷病毒1型对共受体的利用情况并非中和敏感性的主要决定因素。
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
作者信息
LaCasse R A, Follis K E, Moudgil T, Trahey M, Binley J M, Planelles V, Zolla-Pazner S, Nunberg J H
机构信息
Montana Biotechnology Center, The University of Montana, Missoula 59812, USA.
出版信息
J Virol. 1998 Mar;72(3):2491-5. doi: 10.1128/JVI.72.3.2491-2495.1998.
Abstract
We have examined the relationship between coreceptor utilization and sensitivity to neutralization in a primary isolate of human immunodeficiency virus type 1 and its T-cell line-adapted (TCLA) derivative. We determined that adaptation of the primary-isolate (PI) virus 168P results in the loss of the unique capacity of PI viruses to utilize the CCR5 coreceptor and in the acquisition by the TCLA 168C virus of sensitivity to neutralization by V3-directed monoclonal antibodies (MAbs). In experiments wherein infection by 168P is directed via either the CCR5 or the CXCR4 pathway, we demonstrate that the virus, as well as pseudotyped virions bearing a molecularly cloned 168P envelope protein, remains refractory to neutralization by MAbs 257-D, 268-D, and 50.1 regardless of the coreceptor utilized. This study suggests that coreceptor utilization is not a primary determinant of differential neutralization sensitivity in PI and TCLA viruses.
摘要
我们研究了1型人类免疫缺陷病毒的一株原代分离株及其T细胞系适应株（TCLA）中辅助受体利用与中和敏感性之间的关系。我们确定，原代分离株（PI）病毒168P的适应性变化导致PI病毒利用CCR5辅助受体的独特能力丧失，以及TCLA 168C病毒获得对V3定向单克隆抗体（MAb）中和的敏感性。在通过CCR5或CXCR4途径进行168P感染的实验中，我们证明，该病毒以及携带分子克隆的168P包膜蛋白的假型病毒颗粒，无论使用何种辅助受体，对MAb 257-D、268-D和50.1的中和均具有抗性。这项研究表明，辅助受体的利用不是PI和TCLA病毒中和敏感性差异的主要决定因素。
相似文献
1
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.人类免疫缺陷病毒1型对共受体的利用情况并非中和敏感性的主要决定因素。
J Virol. 1998 Mar;72(3):2491-5. doi: 10.1128/JVI.72.3.2491-2495.1998.
2
Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.人免疫缺陷病毒1型新衍生的适应T细胞系的分离株对CCR5共受体的持续利用
J Virol. 1998 Sep;72(9):7603-8. doi: 10.1128/JVI.72.9.7603-7608.1998.
3
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.在CCR5限制性而非CXCR4利用型的原发性人类免疫缺陷病毒1型毒株的天然包膜糖蛋白寡聚体中，一个保守的、CD4诱导性V3环中和表位的隐秘性质。
J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005.
4
Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.小胶质细胞适应性1型人类免疫缺陷病毒及其亲本毒株包膜之间CD4/CCR5利用差异、gp120构象及中和敏感性
J Virol. 2001 Apr;75(8):3568-80. doi: 10.1128/JVI.75.8.3568-3580.2001.
5
Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.V1区的N-连接寡糖对寡聚化人免疫缺陷病毒1型糖蛋白120 V3环中中和表位的保护作用。
AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1067-76. doi: 10.1089/088922201300343753.
6
Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.将V3环作为参与中和1型人类免疫缺陷病毒原代分离株与T细胞系适应株的抗体的靶表位的研究。
J Virol. 1998 Dec;72(12):9855-64. doi: 10.1128/JVI.72.12.9855-9864.1998.
7
Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.1型人类免疫缺陷病毒原代分离株及T细胞系适应株的中和作用：V3特异性抗体的作用
J Gen Virol. 1998 Jan;79 ( Pt 1):77-82. doi: 10.1099/0022-1317-79-1-77.
8
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.HIV-1包膜蛋白V3环截短赋予对共受体抑制剂的抗性并增强对中和抗体的敏感性。
PLoS Pathog. 2007 Aug 24;3(8):e117. doi: 10.1371/journal.ppat.0030117.
9
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.2型人类免疫缺陷病毒共受体使用情况、自身中和作用、包膜序列及糖基化的演变
J Gen Virol. 2005 Dec;86(Pt 12):3385-3396. doi: 10.1099/vir.0.81259-0.
10
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.可变区3（V3）突变决定了一种与广泛交叉反应的原发性病毒中和抗体反应相关的人类免疫缺陷病毒1型包膜的整体中和表型和不依赖CD4的感染性。
J Virol. 2002 Jan;76(2):644-55. doi: 10.1128/jvi.76.2.644-655.2002.
引用本文的文献
1
Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.体液免疫压力选择使用CXC趋化因子受体4的HIV-1变体。
EBioMedicine. 2016 Jun;8:237-247. doi: 10.1016/j.ebiom.2016.04.040. Epub 2016 May 5.
2
Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.具有趋化因子受体CXCR4嗜性的猿猴免疫缺陷病毒SIVmac239变体的衍生与特性分析
J Virol. 2009 Oct;83(19):9911-22. doi: 10.1128/JVI.00533-09. Epub 2009 Jul 15.
3
Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.与同一患者共存的利用CCR5的病毒变体相比，最近出现的利用CXCR4的人类免疫缺陷病毒1型毒株的中和敏感性增加。
J Virol. 2007 Jan;81(2):525-31. doi: 10.1128/JVI.01983-06. Epub 2006 Nov 1.
4
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.从单一血浆样本中分离出的1型人类免疫缺陷病毒变体表现出广泛的中和敏感性。
J Virol. 2005 Sep;79(18):11848-57. doi: 10.1128/JVI.79.18.11848-11857.2005.
5
Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.在CCR5限制性而非CXCR4利用型的原发性人类免疫缺陷病毒1型毒株的天然包膜糖蛋白寡聚体中，一个保守的、CD4诱导性V3环中和表位的隐秘性质。
J Virol. 2005 Jun;79(11):6957-68. doi: 10.1128/JVI.79.11.6957-6968.2005.
6
Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.与重组1型人类免疫缺陷病毒（HIV）gp120包膜糖蛋白相比，受限单克隆抗体A32-HIV Env gp120复合物的免疫原性。
J Virol. 2004 May;78(10):5270-8. doi: 10.1128/jvi.78.10.5270-5278.2004.
7
Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41.gp41中央胞外域中疏水残基在维持人类免疫缺陷病毒1型包膜糖蛋白亚基gp120和gp41之间结合中的作用。
J Virol. 2004 May;78(9):4921-6. doi: 10.1128/jvi.78.9.4921-4926.2004.
8
Inhibition of HIV-1 infection by monoclonal antibodies to carbohydrates of Schistosoma mansoni.
Med Microbiol Immunol. 2005 Jan;194(1-2):61-5. doi: 10.1007/s00430-003-0214-x.
9
Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.在CRF01_AE亚型感染患者中，1型人类免疫缺陷病毒原代分离株的中和抗性与合胞体诱导表型及较低的CD4细胞计数相关。
J Virol. 2003 Aug;77(15):8570-6. doi: 10.1128/jvi.77.15.8570-8576.2003.
10
Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.基于gp120与CD4及共受体的序列相互作用，单链嵌合蛋白sCD4-17b对1型人类免疫缺陷病毒的中和作用。
J Virol. 2003 Mar;77(5):2859-65. doi: 10.1128/jvi.77.5.2859-2865.2003.
本文引用的文献
1
HIV entry and tropism: the chemokine receptor connection.HIV进入与嗜性：趋化因子受体联系
AIDS. 1997;11 Suppl A:S3-16.
2
Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.1型和2型人类免疫缺陷病毒以及猿猴免疫缺陷病毒的包膜糖蛋白可将人类CCR5用作病毒进入的共受体，并与这种趋化因子受体进行直接的CD4依赖性相互作用。
J Virol. 1997 Sep;71(9):6296-304. doi: 10.1128/JVI.71.9.6296-6304.1997.
3
Human immunodeficiency virus type 1 vpr gene induces phenotypic effects similar to those of the DNA alkylating agent, nitrogen mustard.1型人类免疫缺陷病毒vpr基因诱导出与DNA烷化剂氮芥类似的表型效应。
J Virol. 1997 May;71(5):3961-71. doi: 10.1128/JVI.71.5.3961-3971.1997.
4
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.共受体使用情况的变化与HIV-1感染个体的疾病进展相关。
J Exp Med. 1997 Feb 17;185(4):621-8. doi: 10.1084/jem.185.4.621.
5
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.CCR3和CCR5是小胶质细胞被HIV-1感染的共受体。
Nature. 1997 Feb 13;385(6617):645-9. doi: 10.1038/385645a0.
6
Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.原发性、诱导合胞体的1型人类免疫缺陷病毒分离株具有双嗜性，大多数可使用Lestr或CCR5作为病毒进入的共受体。
J Virol. 1996 Dec;70(12):8355-60. doi: 10.1128/JVI.70.12.8355-8360.1996.
7
CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.HIV-2的非CD4依赖性感染由趋化因子/ CXCR4介导。
Cell. 1996 Nov 15;87(4):745-56. doi: 10.1016/s0092-8674(00)81393-8.
8
HIV-1 subtype and second-receptor use.HIV-1亚型及第二受体的使用情况。
Nature. 1996 Oct 31;383(6603):768. doi: 10.1038/383768a0.
9
10
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.CXC趋化因子SDF-1是LESTR/fusin的配体，可预防经T细胞系适应的HIV-1感染。
Nature. 1996 Aug 29;382(6594):833-5. doi: 10.1038/382833a0.
Zotero 插件